We are driven to enhance cancer medicine
Bavituximab is an investigational immune-modulatory monoclonal antibody that blocks activation by phosphatidylserine (PS) of TAM and TIM receptors on immune cells. PS is a phospholipid exposed on the surface of stressed tumor cells and tumor blood vessels. PS induces immunological non-responsiveness and reduces the ability of immune cells to recognize and fight tumors.
Oncologie acquired Bavituximab from Avid Bioservices, Inc. in February 2018.
Lefitolimod is an immunomodulator and toll-like receptor 9 (TLR-9) agonist. It is a small, covalently closed DNA molecule that is taken up by dendritic cells and other immune cells mimicking bacterial or viral infection and activating TLR-9. Consequent production of pro-inflammatory cytokines jump-starts innate and adaptive immune responses and anti-tumor activity.
Oncologie signed an agreement with Mologen AG in February 2018 regarding lefitolimod. Under the agreement, Oncologie has the exclusive license to develop, manufacture & commercialize lefitolomid in China, Taiwan, Singapore, Hong Kong and Macao. In addition, Oncologie and Mologen AG will co-develop the compound globally.
Varisacumab is an investigational monoclonal antibody that uniquely blocks the epitope for vascular endothelial growth factor A (VEGFA), binding only to VEGF Receptor 2 (VEGFR2). VEGF is a validated cancer pathway, and new understanding shows the importance of selectivity on the receptor VEGFR2 compared to VEGFR1.
Oncologie acquired Varisacumab from Avid Bioservices, Inc. in October 2018.